<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03763318</url>
  </required_header>
  <id_info>
    <org_study_id>EQ001-aGVHD-001</org_study_id>
    <nct_id>NCT03763318</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD</brief_title>
  <acronym>EQUATE</acronym>
  <official_title>A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Equillium</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocon Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Equillium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical
      activity of EQ001 in subjects with Acute Graft Versus Host Disease (aGVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll approximately 84 subjects in two (2) parts:

      Part A is an open label study and will enroll approximately 24 evaluable subjects with aGVHD
      across 4 cohorts. The total number of patients will depend on the number of dose escalations
      necessary to enable a decision to be made on the recommended dose to take forward into Part B
      of the study. The planned dose escalation will start with cohort 1, where subjects will
      receive EQ001 administered intravenously every two weeks for a total of 5 doses.

      Part B is a randomized, double-blind, placebo-controlled study and will enroll approximately
      60 additional subjects, randomized in a 2:1 ratio to either active treatment EQ001 (40) or
      placebo (20). Subjects will receive either EQ001 or placebo administered intravenously every
      two weeks for a total of 5 doses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A is an open label 3+3 dose escalation Part B is blinded and randomized 2:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part B will be blinded to all study staff that has direct access to the subjects and the sponsor. The site's pharmacist or designee will be unblinded to prepare the study drug.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>Study Day 85</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in aGVHD organ stages and overall clinical grading, aGVHD-AI</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Clinical activity will be assessed by change from baseline in aGVHD organ stages and overall clinical grading, aGVHD-AI, concomitant medication usage and disease progression assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum EQ001serum concentration, Tmax</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Time to maximum EQ001 serum concentration, Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum EQ001 serum drug concentration, Cmax</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Maximum EQ001 serum drug concentration, Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum EQ001 serum drug concentration, Cmin</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Minimum EQ001 serum drug concentration prior to next dose, Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total EQ001 exposure across time, AUC (from zero to infinity)</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Total EQ001 exposure across time, AUC (from zero to infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life of EQ001, t1/2</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Half life of EQ001, t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of EQ001, Vd</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Volume of distribution of EQ001, Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance, Cl</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Clearance, Cl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>Study Day 337</time_frame>
    <description>Including but not limited to: IL-1β, IL-2, IL-6, IL-17, IL-21, IL-22, IL-23, IFN-γ, and TGF-β, C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD6 receptor occupancy</measure>
    <time_frame>Study Day 337</time_frame>
    <description>CD6 receptor occupancy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Acute-graft-versus-host Disease</condition>
  <condition>aGVHD</condition>
  <condition>GVHD</condition>
  <condition>GVHD, Acute</condition>
  <arm_group>
    <arm_group_label>EQ001 Dose Escalation (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EQ001 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EQ001 Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EQ001</intervention_name>
    <description>Itolizumab [Bmab 600])</description>
    <arm_group_label>EQ001 (Part B)</arm_group_label>
    <arm_group_label>EQ001 Dose Escalation (Part A)</arm_group_label>
    <other_name>Bmab600</other_name>
    <other_name>Itolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EQ001 Placebo</intervention_name>
    <description>EQ001 Placebo</description>
    <arm_group_label>EQ001 Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject at least 18 years of age for Part A, and at least 12 years of
             age for Part B.

          2. Recipients of allogeneic hematopoietic stem cell transplantation (alloHSCT) using
             myeloablative or non myeloablative conditioning regimens.

          3. Have a clinical diagnosis of acute GVHD requiring systemic immune suppressive therapy.

          4. Deemed by the investigator to be likely to comply with the planned procedure as
             required by the protocol for the duration of the study

        Exclusion Criteria:

          1. Presence of morphologic relapsed primary malignancy, treatment for relapse after
             alloHSCT was performed, or requirement for rapid immunosuppressive treatment
             withdrawal for early malignancy relapse.

          2. Evidence of graft failure based on cytopenia(s), and as determined by the
             investigator.

          3. Evidence of post-transplant lymphoproliferative disease.

          4. Any prior therapy for acute GVHD, except for alloHSCT prophylaxis regimens or
             systemically administered corticosteroids.

          5. As determined by the investigator, any medical, psychiatric, or other condition or
             circumstance that is likely to negatively affect: the subject's participation in this
             clinical study, the subject's safety, or the reliability of the study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krishna Polu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Equillium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vice President, Development Operations</last_name>
    <phone>858-412-5302</phone>
    <email>jrothman@equilliumbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Tran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Taddeo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami - Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirenia Correa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Burton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelique Brooks</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Jennings</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan - C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggi Kennel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University and Barnes Jewish Heart &amp; Vascular Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Record</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Nichols</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janell Markey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindi Yost</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Channing Dudley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriStar Centennial Medical Center (SCRI)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Shore</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital (SCRI)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dion Holmes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cary Golden</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-4433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoAnn Lorenz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; the Medical College of Wisconsin Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://equilliumbio.com</url>
    <description>Company website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

